At Janssen we strive for excellence and, as a partner in pulmonary hypertension, we are committed to delivering high quality medical education whilst providing a platform for knowledge exchange and innovation. To help us achieve this we are privileged to have the support and participation of the internationally renowned experts who form our scientific committee and faculties. Their involvement ensures we continue to provide clinically relevant and balanced medical education.
The Pulmonary Hypertension Academy is a source of medical education materials that have been developed with several leading international independent experts in the field of pulmonary hypertension and beyond. By clicking on “SEE EXPERT OPINIONS” you will have the opportunity to register and access archived video broadcasts from medical education meetings. (access varies depending on country regulations)
Multidisciplinary expert panel shares their experience of PAH patient management and COVID-19.
The management of pulmonary arterial hypertension (PAH) continues to advance with evolving treatment strategies based on clinical trial data. These data provide evidence for the optimal application of therapies that when used alone, in combination, and/or added sequentially can help patients with PAH or related complications meet their treatment goals. This engaging collection of CME activities is designed to support clinicians caring for patients with PAH in leveraging the latest research and clinical pearls for practice.
*supported by an independent educational grant from Janssen Pharmaceutical Company of Johnson and Johnson
The new podcast and videocast series bringing you expert perspectives in pulmonary hypertension (PH). Tune in to our bitesize episodes, where leading experts will discuss key aspects and hot topics in the management of PH. Watch this space for regular releases.
The World Scleroderma Foundation is dedicated to initiating and supporting research in scleroderma in all its aspects in all regions of the world. It is also committed to improving the quality of life for scleroderma sufferers and their families.
To facilitate patient oriented research both independently and in collaboration with other existing organisations and international societies working in this field.
The European Pediatric Pulmonary Vascular Disease Network e.V. is a non-profit organisation. The leadership board of the network consists of the founding members, i.e. medical doctors (pediatric cardiologists, intensivists, neonatologists), basic-translational scientists, a medical journalist and an attorney, with a broad range of expertise and experience.
We unite national cardiac societies from around the world. This unique network allows us to understand the impact of cardiovascular disease and how we can better reduce its burden. Our diversity is our strength.
ERS annual congress is a showcase of excellence across the entire field of respiratory medicine, and ERS is committed to supporting the respiratory community to connect, share the latest scientific data and access educational opportunities during these challenging times.
The European League against Rheumatism (EULAR) promotes prevention and treatment of rheumatic diseases and supports research by various healthcare professionals as well as scientific societies.
In the last decade, the six world congresses have contributed to the knowledge about scleroderma all over the world. Colleagues from different specialties, junior trainees, health professionals and patients have gathered together and they have profited by challenging programmes including clinical experience, interactive sessions and basic science. Along with the medical component of the congress, the patient program has grown with increasing attendance and extended lectures subjects.
Under the Auspices of World Scleroderma Foundation
ITEM CODE: CP-204030 | DATE OF PREPARATION: January 2021
